CARDIOVASCULAR MEDICINE

Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy

P Di Napoli¹, A A Taccardi¹, A Barsotti²

¹ Department of Cardiology, Intensive Care Unit, Casa di Cura Villa Pini d’Abruzzo, Chieti, Italy
² Department of Internal Medicine, University of Genoa, Genoa, Italy

Correspondence to:
Correspondence to:
Dr Pericle Di Napoli
Dipartimento di Cardiologia-UTIC, Casa di Cura Villa Pini d’Abruzzo, Via dei Frentani 228, 66100 Chieti, Italy; dinapoli{at}unich.it

Objective: To investigate the long term effects of trimetazidine in patients with dilated ischaemic cardiomyopathy. The effects of trimetazidine on left ventricular function as well as its tolerability profile and potential anti-inflammatory effects were studied.

Design: 61 patients were randomly assigned either to receive trimetazidine (20 mg thrice daily) in addition to their conventional treatment or to continue their usual drug treatment for 18 months. Patients were evaluated at baseline and at 6, 12, and 18 months with a clinical examination, echocardiography, and biochemical analysis (C reactive protein).

Results: Trimetazidine added to the usual treatment significantly improved the patients’ functional status (assessed by New York Heart Association functional class). The functional improvement of trimetazidine treated patients was associated with a significant increase in left ventricular ejection fraction (30 (6)%, 32 (8)%, 38 (7)%, and 37 (6)% v 31 (8)%, 30 (7)%, 28 (6)%, and 26 (9)% in control patients at baseline and at 6, 12, and 18 months, respectively) and with a significant effect on ventricular remodelling. C reactive protein plasma concentrations remained stable throughout the study in patients receiving trimetazidine (2.5 (1.0), 2.7 (2.0), 2.7 (3.0), and 3.0 (2.0) mg/l at baseline and at 6, 12, and 18 months, respectively) but increased significantly in the control group (2.4 (1.0), 3.4 (1.2), 6.0 (4.0), and 7.0 (5.0) mg/l, respectively). No significant adverse event or changes in clinical or biochemical parameters were detected.

Conclusion: Treatment with trimetazidine added to the usual treatment for up to 18 months was well tolerated and induced a functional improvement in patients with dilated cardiomyopathy. Trimetazidine treatment was associated with a significant improvement of left ventricular function and the remodelling process. Results also suggest that the inflammatory response was limited in patients treated with trimetazidine.

Abbreviations: ACE, angiotensin converting enzyme; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association

Keywords: randomised study; trimetazidine; ischaemic dilated cardiomyopathy; cardioprotection; inflammatory process

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ashrafian, H., Frenneaux, M. P., Opie, L. H. (2007). Metabolic Mechanisms in Heart Failure. Circulation 116: 434-448 [Abstract] [Full Text]  
• Neubauer, S. (2007). The Failing Heart -- An Engine Out of Fuel. NEJM 356: 1140-1151 [Full Text]  
• Tang, W.H. W. (2006). Metabolic Approach in Heart Failure: Rethinking How We Translate From Theory to Clinical Practice. J Am Coll Cardiol 48: 999-1000 [Full Text]  
• Fragasso, G., Palloshi, A., Puccetti, P., Silipigni, C., Rossodivita, A., Pala, M., Calori, G., Alfieri, O., Margonato, A. (2006). A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure. J Am Coll Cardiol 48: 992-998 [Abstract] [Full Text]  
• Lopaschuk, G. D. (2006). Optimizing cardiac Fatty Acid and glucose metabolism as an approach to treating heart failure.. SEMIN CARDIOTHORAC VASC ANESTH 10: 228-230 [Abstract]  
• Fragasso, G., Perseghin, G., De Cobelli, F., Esposito, A., Palloshi, A., Lattuada, G., Scifo, P., Calori, G., Del Maschio, A., Margonato, A. (2006). Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 27: 942-948 [Abstract] [Full Text]  
• DeGrado, T. R., Kitapci, M. T., Wang, S., Ying, J., Lopaschuk, G. D. (2006). Validation of 18F-Fluoro-4-Thia-Palmitate as a PET Probe for Myocardial Fatty Acid Oxidation: Effects of Hypoxia and Composition of Exogenous Fatty Acids. JNM 47: 173-181 [Abstract] [Full Text]  
• Morrow, D. A., Givertz, M. M. (2005). Modulation of Myocardial Energetics: Emerging Evidence for a Therapeutic Target in Cardiovascular Disease. Circulation 112: 3218-3221 [Full Text]  
• Lee, L., Campbell, R., Scheuermann-Freestone, M., Taylor, R., Gunaruwan, P., Williams, L., Ashrafian, H., Horowitz, J., Fraser, A. G., Clarke, K., Frenneaux, M. (2005). Metabolic Modulation With Perhexiline in Chronic Heart Failure: A Randomized, Controlled Trial of Short-Term Use of a Novel Treatment. Circulation 112: 3280-3288 [Abstract] [Full Text]  
• O'Meara, E, McMurray, J J V (2005). Myocardial metabolic manipulation: a new therapeutic approach in heart failure?. Heart 91: 131-132 [Abstract] [Full Text]